<DOC>
	<DOCNO>NCT02892344</DOCNO>
	<brief_summary>The purpose trial evaluate efficacy safety QMF149 150/80 microgram o.d . deliver via Concept1 compare MF 200 microgram o.d. , deliver via Twisthaler® term lung function symptom control poorly ( ie inadequately ) control asthma patient . This study assess contribution LABA add-on therapy low dose ICS monotherapy .</brief_summary>
	<brief_title>Study QMF149 ( 150/80 µg ) Compared With MF Twisthaler® ( 200 µg ) Patients With Asthma</brief_title>
	<detailed_description>The primary objective study demonstrate superiority QMF149 150/80 microgram o.d . ( even ) deliver via Concept1 compare MF 200 microgram o.d . ( even ) deliver via Twisthaler® term trough FEV1 12 week treatment adult adolescent . The key secondary objective study demonstrate superiority QMF149 150/80 microgram MF 200 microgram o.d . term ACQ-7 12 week treatment .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Mometasone Furoate</mesh_term>
	<criteria>Patients document diagnosis asthma period least 3 month prior Screening Visit Patients use low dose ICS , without controller ( ie , LABA , Leukotriene Receptor Antagonist ) stable dose least 1 month prior Screening Visit Adult patient symptomatic screen despite treatment exist therapy . Patients ACQ7 score ≥ 1.5 Visit 101 Visit 102 ( inadequately control ) . Adolescent patient : If take ICS ( without LABA ) symptomatic screen despite treatment low dos ICS . These patient must ACQ7 score ≥ 1.5 Visit 101 Visit 102 . If take ICS ( low dose ) / LABA , ACQ7 score ≥1 &lt; 1.5 Visit 101 : must ACQ7 score≥1.5 Visit 102 ( prior randomization ) . Prebronchodilator FEV1≥ 60 % &lt; 90 % predict normal value patient withhold bronchodilator Visits 101 102 Patients demonstrate increase FEV1 12 % ≥ 200 mL within 30 minute administration 400 microgram salbutamol/360 microgram albuterol ( equivalent dose ) Visit 101 . Patients smoke inhaled tobacco product ( include electronic cigarette ) within 6 month period prior Visit 1 , smoke history great equal 10 pack year . Patients asthma attack/exacerbation require systemic steroid hospitalization ( &gt; 24 hour ) emergency room visit ( ≤ 24 hour ) follow : For adult : within 6 week Screening Visit . If patient experience asthma attack/exacerbation require systemic steroid emergency room visit Visit 1 Visit 102 may rescreened 6 week recovery exacerbation For adolescent : Exacerbation require systemic steroid , hospitalization ( &gt; 24 hour ) emergency room visit ( ≤24 hour ) within 6 month , prior visit 1 . Patients ever require intubation severe asthma attack/exacerbation Patients clinical condition ( eg . glaucoma , cataract fragility fracture ) may worsen ICS administration ( accord investigator 's medical judgment ) Patients respiratory tract infection asthma worsen within 4 week prior Screening Visit Visit 1and Visit 102 . Patients may rescreened 4 week recovery respiratory tract infection asthma worsen . Patients chronic condition affect upper respiratory tract ( eg . chronic sinusitis ) opinion investigator may interfere study . Patients history chronic lung disease asthma , include ( limited ) COPD , sarcoidosis , interstitial lung disease , cystic fibrosis , clinically significant bronchiectasis active tuberculosis . Patients Type I diabetes uncontrolled Type II diabetes . Patients narcolepsy and/or insomnia . Patients Maintenance Immunotherapy ( desensitization ) allergies less 3 month prior Visit 101 patient Maintenance Immunotherapy 3 month prior Visit 101 expect change throughout course study . Patients diagnose rare hereditary problem galactose intolerance , Lapp lactase deficiency glucosegalactose malabsorption know intolerance lactose milk product .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Phase III , blind , QMF149 , Mometasone furoate ( MF ) , mild asthma , Adolescent , adult</keyword>
</DOC>